Evotec stock: At 63.29 percent below its high, Evotec stock trades at EUR 2.68

Published on 10/20/2026 at 15:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 52-week low is EUR 2.41 as of October 20, 2026. Evotec stock costs EUR 2.68 on October 20, 2026, up 1.90 percent versus the Xetra close.

Price range and reporting date

The 52-week high was EUR 7.30 for Evotec as of October 20, 2026.
Full third-quarter and nine-month results are scheduled for November 5, 2026.
Evotec stock costs EUR 2.68 at Lang & Schwarz on October 20, 2026 at 3:35 p.m. CEST, 1.90 percent above the Xetra close of October 19, 2026, 63.29 percent below the 52-week high.

Geometrisches Bauhaus-Poster in Rot Gelb Blau mit großem Schriftzug PHARMA — Bauhaus-Poster mit geometrischen Formen und Schriftzug PHARMA steht sinnbildlich für Evotec SE, ISIN DE0005664809, Biotech-Branche, Illustration mit AI erstellt.

Evotec SE (ISIN DE0005664809) was 63.29 percent below its 52-week high of EUR 7.30 on October 20, 2026. The range leaves the stock close to its yearly low of EUR 2.41, while the next full results are scheduled for November 5, 2026. Evotec was trading at EUR 2.68 at Lang & Schwarz on October 20, 2026 at 3:35 p.m. CEST, up 1.90 percent versus the Xetra close of October 19, 2026 at EUR 2.63.

The yearly range stays wide

The 52-week range runs from EUR 2.41 to EUR 7.30 as of October 20, 2026. At 444,607 shares, trading volume was accompanied by a market capitalization of EUR 474.2 million. The distance from the current price to the yearly high is 63.29 percent, calculated from EUR 2.68 and EUR 7.30.

Evotec operates in drug discovery and development, combining research partnerships with data-driven and artificial-intelligence-supported platforms. Its investor-relations page describes collaborations spanning pharmaceutical and biotechnology development, including fee-for-service work, integrated discovery alliances and licensing arrangements.

Valuation and the next date

Evotec's trailing price-to-earnings ratio was minus 2.38 as of October 20, 2026, reflecting a negative earnings base. The company is scheduled to publish its full third-quarter and first nine-month results on November 5, 2026, according to StockTitan.

The preliminary first nine-month figures announced on October 13, 2026 included revenue of EUR 465.0 million and adjusted EBITDA of minus EUR 42.8 million. The same release reaffirmed full-year revenue guidance of EUR 570 million to EUR 610 million and adjusted EBITDA guidance of minus EUR 70 million to minus EUR 105 million, with the variance against expectations attributed mainly to the timing of consensus estimates by StockTitan.

Evotec and peer valuations

Evotec: up 1.90 percent, price-to-earnings ratio minus 2.38, market capitalization EUR 474.2 million.

Bayer (Xetra, EUR): up 0.16 percent, price-to-earnings ratio minus 24.65, market capitalization EUR 42.7 billion.

Sartorius (Xetra, EUR): up 1.19 percent, price-to-earnings ratio 93.11, market capitalization EUR 16.3 billion.

What the range says

The stock's 63.29 percent gap to the yearly high contrasts with a 11.20 percent rise from the EUR 2.41 low. The November 5 reporting date is the next scheduled point for comparing revenue, adjusted EBITDA and guidance with the preliminary figures.

Evotec was trading at EUR 2.68 at Lang & Schwarz on October 20, 2026 at 3:35 p.m. CEST, up 1.90 percent versus the Xetra close of October 19, 2026 at EUR 2.63. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.